• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals

09/05/2017 by Intellectual Property Watch 1 Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

By Elise De Geyter for Intellectual Property Watch

The 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement negotiations is taking place this week in Manila, Philippines. Health activists warn that Japan and South Korea are pushing for measures that go beyond international trade rules on intellectual property, including extending patent terms and data exclusivity in countries such as India, a primary source of cheaper generic medicines.

Médecins Sans Frontières (MSF – Doctors Without Borders) in its response is urging Japan and South Korea to withdraw their proposals as it considers them as being harmful. The proposed measures would lead to a delay in generic competition and strongly increase the prices of medicines for patients all over the world, MSF said.

At issue are proposed measures to update the 1994 World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). So-called TRIPS-plus measures being put forward include the extension of the drug companies’ patent terms and the establishment of new monopolies in the national drug regulatory system (data exclusivity).

The proposed investor-state dispute settlement (ISDS) provision could possibly hinder the capacity of governments to implement and execute policies to protect and ensure universal health care, and would increase the risk of governments to be sued by pharmaceutical companies for millions of dollars, the group said.

In addition, the draft ‘IP Enforcement’ text of RCEP does not contain adequate safeguard measures against possible abuse, according to MSF. The draft text neither guarantees the flow of generic medicines from producers to patients. MSF has asked the negotiators to consider the deletion of patents and test data from the enforcement section.

The RCEP includes the ten members of the Association of Southeast Asian Nations (ASEAN) and six other countries – India, China, Japan, Australia, New Zealand and South Korea.

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, Bilateral/Regional Negotiations, English, Health & IP, Health Policy Watch, Lobbying, Patents/Designs/Trade Secrets

Trackbacks

  1. MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals – WebLegal says:
    10/05/2017 at 10:04 am

    […] and data exclusivity in countries such as India, a primary source of cheaper generic medicines. Fonte:https://www.ip-watch.org/2017/05/09/msf-warns-threats-public-health-asian-trade-agreement-ip-p… Author: Intellectual Property […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Top Global Health stories

New WHO Director Tedros’s Opening Vision: People First

Enter The African Medicines Agency, Continent’s First Super-Regulator?

More health stories...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2025 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.